Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evolution of β-lactamase-mediated cefiderocol resistance
Christopher Frøhlich, Vidar Sørum, Nobuhiko Tokuriki, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 77, Iss. 9, pp. 2429-2436
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2023)
Open Access | Times Cited: 476
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex
Mariana Castanheira, Rodrigo E. Mendes, Ana Cristina Gales
Clinical Infectious Diseases (2023) Vol. 76, Iss. Supplement_2, pp. S166-S178
Open Access | Times Cited: 81
Epistasis arises from shifting the rate-limiting step during enzyme evolution of a β-lactamase
Christopher Frøhlich, H. Adrian Bunzel, Karol Buda, et al.
Nature Catalysis (2024) Vol. 7, Iss. 5, pp. 499-509
Open Access | Times Cited: 15
Disc Diffusion and ComASP® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
Gabriele Bianco, Matteo Boattini, Sara Comini, et al.
Antibiotics (2023) Vol. 12, Iss. 3, pp. 604-604
Open Access | Times Cited: 19
Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
Mustafa Sadek, Rémi Le Guern, Éric Kipnis, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2022) Vol. 42, Iss. 1, pp. 61-66
Open Access | Times Cited: 23
Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022–2023
Jacqueline Findlay, Otávio Hallal Ferreira Raro, Laurent Poirel, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 3, pp. 551-557
Open Access | Times Cited: 5
Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coli
Nicolas Helsens, Mustafa Sadek, Christophe Le Terrier, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024)
Closed Access | Times Cited: 5
Combating Metallo-β-Lactamase-Producing Pseudomonas aeruginosa: The Fractional Inhibitory Concentration Index as a Tool to Evaluate Antibiotic Synergy
Guido Granata, Carolina Venditti, Claudia Rotondo, et al.
Antibiotics (2025) Vol. 14, Iss. 2, pp. 210-210
Open Access
Siderophore cephalosporins
Malcolm G. P. Page
EcoSal Plus (2025)
Closed Access
High-level ceftazidime/avibactam resistance inEscherichia coliconferred by the novel plasmid-mediated β-lactamase CMY-185 variant
William C. Shropshire, Bradley T. Endres, Jovan Borjan, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 10, pp. 2442-2450
Closed Access | Times Cited: 12
Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy
Gabriele Arcari, Federico Cecilia, Alessandra Oliva, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 11
Open Access | Times Cited: 12
The mechanism of ceftazidime and cefiderocol hydrolysis by D179Y variants of KPC carbapenemases is similar and involves the formation of a long-lived covalent intermediate
André Birgy, Christina Nnabuife, Timothy Palzkill
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 3
Open Access | Times Cited: 4
Cefiderocol: Clinical application and emergence of resistance
Liang Wang, Jie Zhu, Liang Chen, et al.
Drug Resistance Updates (2023) Vol. 72, pp. 101034-101034
Closed Access | Times Cited: 10
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol
Gabriele Bianco, Matteo Boattini, Monica Cricca, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 12, pp. 14132-14153
Open Access | Times Cited: 3
Emerging Target-Directed Approaches for the Treatment and Diagnosis of Microbial Infections
Mariana C. Almeida, Paulo Martins da Costa, Emı́lia Sousa, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 32-70
Closed Access | Times Cited: 14
Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility
Vyanka Mezcord, Jenny Escalante, Brent Nishimura, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11752-11752
Open Access | Times Cited: 7
Fluorinated captopril analogues inhibit metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose
Alexandra A. Kondratieva, Katarzyna Palica, Christopher Frøhlich, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116140-116140
Open Access | Times Cited: 2
The Role of the Respiratory Microbiome in the Pathogenesis of Aspiration Pneumonia: Implications for Diagnosis and Potential Therapeutic Choices
Natalia G. Vallianou, Alexandros Skourtis, Dimitris Kounatidis, et al.
Antibiotics (2023) Vol. 12, Iss. 1, pp. 140-140
Open Access | Times Cited: 6
Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa
Xavier Vuillemin, Maëlle Da Silva, Maxime Bour, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 3, pp. 106917-106917
Closed Access | Times Cited: 6
Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms
Gabriele Bianco, Paolo Gaibani, Sara Comini, et al.
Antibiotics (2022) Vol. 11, Iss. 12, pp. 1681-1681
Open Access | Times Cited: 9
Emergence of a clinical Salmonella enterica serovar 1,4,[5], 12: i:-isolate, ST3606, in China with susceptibility decrease to ceftazidime-avibactam carrying a novel blaCTX-M-261 variant and a blaNDM-5
Jie Wei, Shimei Shen, Qinghuan Zhang, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 5, pp. 829-840
Open Access | Times Cited: 1
Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline
Ghady Haidar, Ellen G Kline, Georgios D. Kitsios, et al.
JAC-Antimicrobial Resistance (2024) Vol. 6, Iss. 5
Open Access | Times Cited: 1
Genomic Characterization of an Extensively Drug-Resistant Extra-Intestinal Pathogenic (ExPEC) Escherichia coli Clinical Isolate Co-Producing Two Carbapenemases and a 16S rRNA Methylase
Mustafa Sadek, Alaaeldin Mohamed Saad, Patrice Nordmann, et al.
Antibiotics (2022) Vol. 11, Iss. 11, pp. 1479-1479
Open Access | Times Cited: 6
A glucose-mediated antibiotic resistance metabolic flux from glycolysis, the pyruvate cycle, and glutamate metabolism to purine metabolism
Jiao Xiang, Shiwen Wang, Tao Yuan, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top